Loading...
Immune-related adverse events in cancer patients treated with immune checkpoint inhibitors: A single-center experience
Immune checkpoint inhibitors (ICIs) like cytotoxic T-lymphocyte-associated protein 4 (anti-CTLA4) and programmed death cell protein 1 (anti-PD1) have revolutionized cancer treatment. As ICI use becomes widespread, more immune-related adverse events (irAE's) are being reported. Our aim was to in...
Na minha lista:
| Udgivet i: | Medicine (Baltimore) |
|---|---|
| Main Authors: | , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Wolters Kluwer Health
2019
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6799752/ https://ncbi.nlm.nih.gov/pubmed/31593084 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MD.0000000000017348 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|